Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3.

Abstract excerpt

Effects of 12 weeks of treatment with pravastatin at a dose of 20 mg/day were compared in subjects with type II hyperlipoproteinemia with apo+(lipoprotein) E phenotype E3/2, E3/3, and E4/3. There were no differences in age, body mass index, smoking status, complications, or plasma levels of lipids and apoproteins, except the higher levels of apo E in E3/2 subjects (n = 11) than in E3/3 subjects (n = 84) and E4/3...

Topics

• Adult
• Aged
• Analysis of Variance
• Anticholesteremic Agents
• Apolipoprotein E3
• Apolipoprotein E4
• Apolipoproteins
• Apolipoproteins E
• Chi-Square Distribution
• Dose-Response Relationship, Drug
• Female
• Humans
• Hyperlipoproteinemia Type II
• Japan
• Lipids
• Male
• Middle Aged
• Phenotype